Autifony Therapeutics
Autifony Therapeutics is a biotechnology company developing medicines to treat hearing disorders such as hearing loss and tinnitus..
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | £1.3m | Early VC | |
| Total Funding | 000k | ||
| GBP | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (64 %) | 3878 % | (29 %) | (98 %) | 117 % | 42 % | 35 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (506 %) | 69 % | 48 % | (2284 %) | (737 %) | (631 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (297 %) | 73 % | 51 % | (2051 %) | (653 %) | (553 %) | (343 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Autifony Therapeutics is a UK-based pharmaceutical company focused on developing innovative drugs to treat hearing disorders and serious diseases of the central nervous system. The company operates in the biopharmaceutical market, targeting conditions such as schizophrenia, Fragile X syndrome, and various hearing disorders. Autifony's business model revolves around the research and development of novel therapeutics, particularly those involving Kv3 ion channels, which play a crucial role in neuronal signaling. The company generates revenue through the development and potential commercialization of these drugs, as well as through partnerships and licensing agreements. Autifony serves a range of clients including healthcare providers, research institutions, and pharmaceutical companies.
Keywords: biopharmaceutical, hearing disorders, central nervous system, schizophrenia, Fragile X, Kv3 ion channels, novel therapeutics, drug development, UK-based, pioneering science.